-
Mashup Score: 5Patient-Matched Tumor-Normal Sequencing - 14 day(s) ago
During our combined 35 years working to advance diagnostic capabilities for cancer—as a pathologist and as a bioinformatician, respectively—we’ve had the opportunity to help build upon the process called patient-matched tumor-normal (PMTN) sequencing that makes DNA analysis of tumors significantly more accurate.
Source: focusononcology.comCategories: General Medicine NewsTweet
-
Mashup Score: 7
Circulating tumor DNA (ctDNA) has long been established as a highly prognostic biomarker to identify molecular residual disease (MRD) in colorectal cancer (CRC) as well as other solid tumor cancers1. With several MRD-guided trials underway exploring the many ways this technology can improve patient care, coupled with the expanding body of data generated over the last several years supporting tumor-informed MRD testing, clinicians are keen to learn more how to use this technology to help inform treatment decisions today. Listen to the podcast and read the article here below.
Source: focusononcology.comCategories: General Medicine NewsTweet-
Tumor-informed #ctDNA testing is reshaping colorectal cancer management. Adham Jurdi, MD, explains how #MRDtesting informs adjuvant and surveillance decisions, backed by data from CALGB 80702 and BESPOKE CRC. Listen to the podcast: https://t.co/YD9QYl0b1t https://t.co/AmNsqkh1HD
-
-
Mashup Score: 5Patient-Matched Tumor-Normal Sequencing - 17 day(s) ago
During our combined 35 years working to advance diagnostic capabilities for cancer—as a pathologist and as a bioinformatician, respectively—we’ve had the opportunity to help build upon the process called patient-matched tumor-normal (PMTN) sequencing that makes DNA analysis of tumors significantly more accurate.
Source: focusononcology.comCategories: General Medicine NewsTweet-
Discover an innovative approach to therapy selection for patients with advanced cancer. Dive into our latest article on patient-matched tumor-normal (PMTN) sequencing and its impact on precision medicine. #CancerResearch #PMTN #OncoExTra https://t.co/IiE2DD1ZXY https://t.co/8QpMCcn8df
-
-
Mashup Score: 7
Circulating tumor DNA (ctDNA) has long been established as a highly prognostic biomarker to identify molecular residual disease (MRD) in colorectal cancer (CRC) as well as other solid tumor cancers1. With several MRD-guided trials underway exploring the many ways this technology can improve patient care, coupled with the expanding body of data generated over the last several years supporting tumor-informed MRD testing, clinicians are keen to learn more how to use this technology to help inform treatment decisions today. Listen to the podcast and read the article here below.
Source: focusononcology.comCategories: General Medicine NewsTweet-
Tumor-informed #ctDNA testing is reshaping colorectal cancer management. Adham Jurdi, MD, explains how #MRDtesting informs adjuvant and surveillance decisions, backed by data from CALGB 80702 and BESPOKE CRC. Listen to the podcast: https://t.co/YD9QYl0b1t https://t.co/AmNsqkh1HD
-
-
Mashup Score: 5Patient-Matched Tumor-Normal Sequencing - 24 day(s) ago
During our combined 35 years working to advance diagnostic capabilities for cancer—as a pathologist and as a bioinformatician, respectively—we’ve had the opportunity to help build upon the process called patient-matched tumor-normal (PMTN) sequencing that makes DNA analysis of tumors significantly more accurate.
Source: focusononcology.comCategories: General Medicine NewsTweet-
Discover an innovative approach to therapy selection for patients with advanced cancer. Dive into our latest article on patient-matched tumor-normal (PMTN) sequencing and its impact on precision medicine. #CancerResearch #PMTN #OncoExTra https://t.co/IiE2DD1ZXY https://t.co/8QpMCcn8df
-
-
Mashup Score: 7
Circulating tumor DNA (ctDNA) has long been established as a highly prognostic biomarker to identify molecular residual disease (MRD) in colorectal cancer (CRC) as well as other solid tumor cancers1. With several MRD-guided trials underway exploring the many ways this technology can improve patient care, coupled with the expanding body of data generated over the last several years supporting tumor-informed MRD testing, clinicians are keen to learn more how to use this technology to help inform treatment decisions today. Listen to the podcast and read the article here below.
Source: focusononcology.comCategories: General Medicine NewsTweet-
Tumor-informed #ctDNA testing is reshaping colorectal cancer management. Adham Jurdi, MD, explains how #MRDtesting informs adjuvant and surveillance decisions, backed by data from CALGB 80702 and BESPOKE CRC. Listen to the podcast: https://t.co/YD9QYl0b1t https://t.co/AmNsqkh1HD
-
-
Mashup Score: 5Patient-Matched Tumor-Normal Sequencing - 28 day(s) ago
During our combined 35 years working to advance diagnostic capabilities for cancer—as a pathologist and as a bioinformatician, respectively—we’ve had the opportunity to help build upon the process called patient-matched tumor-normal (PMTN) sequencing that makes DNA analysis of tumors significantly more accurate.
Source: focusononcology.comCategories: General Medicine NewsTweet-
Discover an innovative approach to therapy selection for patients with advanced cancer. Dive into our latest article on patient-matched tumor-normal (PMTN) sequencing and its impact on precision medicine. #CancerResearch #PMTN #OncoExTra https://t.co/IiE2DD1ZXY https://t.co/8QpMCcn8df
-
-
Mashup Score: 7
Circulating tumor DNA (ctDNA) has long been established as a highly prognostic biomarker to identify molecular residual disease (MRD) in colorectal cancer (CRC) as well as other solid tumor cancers1. With several MRD-guided trials underway exploring the many ways this technology can improve patient care, coupled with the expanding body of data generated over the last several years supporting tumor-informed MRD testing, clinicians are keen to learn more how to use this technology to help inform treatment decisions today. Listen to the podcast and read the article here below.
Source: focusononcology.comCategories: General Medicine NewsTweet-
Tumor-informed #ctDNA testing is reshaping colorectal cancer management. Adham Jurdi, MD, explains how #MRDtesting informs adjuvant and surveillance decisions, backed by data from CALGB 80702 and BESPOKE CRC. Listen to the podcast: https://t.co/YD9QYl0b1t https://t.co/AmNsqkh1HD
-
-
Mashup Score: 5Patient-Matched Tumor-Normal Sequencing - 1 month(s) ago
During our combined 35 years working to advance diagnostic capabilities for cancer—as a pathologist and as a bioinformatician, respectively—we’ve had the opportunity to help build upon the process called patient-matched tumor-normal (PMTN) sequencing that makes DNA analysis of tumors significantly more accurate.
Source: focusononcology.comCategories: General Medicine NewsTweet-
Discover an innovative approach to therapy selection for patients with advanced cancer. Dive into our latest article on patient-matched tumor-normal (PMTN) sequencing and its impact on precision medicine. #CancerResearch #PMTN #OncoExTra https://t.co/IiE2DD1ZXY https://t.co/8QpMCcn8df
-
-
Mashup Score: 7
Circulating tumor DNA (ctDNA) has long been established as a highly prognostic biomarker to identify molecular residual disease (MRD) in colorectal cancer (CRC) as well as other solid tumor cancers1. With several MRD-guided trials underway exploring the many ways this technology can improve patient care, coupled with the expanding body of data generated over the last several years supporting tumor-informed MRD testing, clinicians are keen to learn more how to use this technology to help inform treatment decisions today. Listen to the podcast and read the article here below.
Source: focusononcology.comCategories: General Medicine NewsTweet-
Tumor-informed #ctDNA testing is reshaping colorectal cancer management. Adham Jurdi, MD, explains how #MRDtesting informs adjuvant and surveillance decisions, backed by data from CALGB 80702 and BESPOKE CRC. Listen to the podcast: https://t.co/YD9QYl0b1t https://t.co/AmNsqkh1HD
-
Discover an innovative approach to therapy selection for patients with advanced cancer. Dive into our latest article on patient-matched tumor-normal (PMTN) sequencing and its impact on precision medicine. #CancerResearch #PMTN #OncoExTra https://t.co/IiE2DD1ZXY https://t.co/8QpMCcn8df